Teaser for “Enrolment and Retention of Women in Clinical Trials”
In the case of diseases that affect women disproportionately, how do best practices to enroll and retain women in clinical trials fare today, and what could be done better? By looking at two examples that affect women more than men, in one case younger women and in the other case older women, challenges and potential solutions will be put forward and discussed so as to identify concrete actions that can be taken.
Panel 5 “Enrolment and Retention of Women in Clinical Trials”, will take the specific examples of multiple sclerosis and Alzheimer’s Disease to examine current practices and possible improvements to how women are recruited for and retained in clinical trials.
The lineup will be as follows:
- Sofia Petersson, a patient living with Alzheimer’s disease & WBP Ambassador, Sweden (Introduction)
- Maya Dusenbery, Author of the book “Doing Harm”, USA (Moderator)
- Erin South, Senior Pharmacist at the FDA Office of Women’s Health, USA
- Anke Salmen, Consultant in Neurology, Deputy head of Ambulatory University Neurocenter, Head of Ambulatory Infusion Unit, Inselspital, Bern University Hospital and University of Bern, Switzerland
- Mercé Boada, Medical Director, Fundacio’ ACE, Barcelona Alzheimer Treatment & Research Center, Spain
- Lisa Mosconi, Director, Women’s Brain Initiative; and Associate Director, Alzheimer’s Prevention Clinic at Weill Cornell Medical College, New York, USA
- Angela O’Neal, Director of Women’s Neurology, Clinical Director of the Neurosciences Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, USA
With speakers with diverse scientific and research backgrounds, perspectives,
and opinions, the discussion will range from personal experience around finding
a clinical trial that is the right fit to whether the percentage of women
enrolled in trial should reflect population distribution, socioeconomic
considerations to ensure that women can be enrolled and retained for the
duration of the clinical trial, and more.
We look forward to sharing current practices, difficulties in clinical trial management, personal experiences, and more with you to understand how a scientific process can be made more human while retaining its scientific validity.
Curious as to what this session builds on? Read about Panel 4 here. As for what comes next? Read about Panel 6 here (that blog will be published tomorrow, Tuesday 29 May 2019).
To see the full program, visit https://www.forum-wbp.com/scientific-program/.
To register to attend the Forum, click here: https://www.forum-wbp.com/register/
